Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Cann Group.
RELATED STOCKHEAD STORIES
Health & Biotech
Check Up: Biotechs are going through a rough patch, but recent ASX IPOs haven’t flopped too badly
Health & Biotech
Weed Week: Will the US Senate pass the MORE act, and Swiss cannabis wellness spas are a thing
Health & Biotech
ASX Health Stocks: Cann to market over-the-counter CBD capsules in Australia
Health & Biotech
ASX Health Stocks: UK FSA welcomes Cann’s CBD capsules onto its approved list
Health & Biotech
Weed Week: Wastewater doesn’t lie, Aussie cannabis consumption increased in 2021
Health & Biotech
ASX Health Stocks: Clinuvel reveals study results, and Cann’s Mildura cannabis facility is a go
Health & Biotech
ASX Health Stocks: Amplia Therapeutics gains momentum on pancreatic cancer drug
News
Market Highlights and 5 ASX Small Caps to watch on Friday
News
Weed Week: France temporarily overturns CBD ban and Canada gets a classy culinary cannabis facility
Health & Biotech
ASX Health Stocks: Weed stock Cann Group gets licence from TGA for its cannabis facility
Health & Biotech
Weed Week: An Aussie company mistakenly named in Taliban weed deal and new research could shake up cannabis driving laws
Health & Biotech
In Canada, cannabis is as big as autos… and these ASX stocks are in for the ride
Director Trades
Directors’ Trades: Otto Buttula buys another $580k of Rhythm Biosciences shares
Health & Biotech
Why haven’t any ASX pot stocks got CBD on Australian pharmacy shelves yet? And when will we see them?
Mining
ASX Pot Stocks: BOD Australia jumps 12% on record $7.52 million revenue for FY21
News
Closing Bell: ASX gains over 0.5pc to reach new record high
News